A 30-year-old woman developed a cough and a mass over her posterior left ribs in February 1993. She was otherwise well, with no relevant past medical or family history, and was not investigated at this time as she was in her fourth pregnancy. Two months later, she developed left sided chest pain radiating around the back, and was thought to have a left pleural effusion. She had a spontaneous vaginal delivery of a healthy girl, after which she had a bronchoscopy and open lung biopsy. The initial diagnosis was of a non-Hodgkin's lymphoma, but the clinical picture was felt to be inconsistent. Therefore, a further biopsy was performed, and a small round cell tumour of the Ewing/PNET type was diagnosed. She was then referred to a specialist centre.
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On examination, she had a mass over her left eighth rib in the posterior axillary line measuring 8 cm x 8 cm, with reduced air entry at the left base. The chest X-ray at presentation is shown in Fig. 1 . CT scan of the chest showed a large left chest wall mass, occupying much of the left hemithorax; the diaphragm was indistinguishable, and the stomach and spleen were displaced (Fig. 2a) . Bone scan showed this to be an isolated breast.
lesion, with diffuse uptake throughout the ninth rib ( Fig. 3) . She was treated initially with chemotherapy devised for patients with poor prognosis Ewing's sarcoma. Five drugs were used: etoposide, vincristine, ifosfamide, and doxorubicin alternating with actinomycin D (Fig. 4) . Her pain resolved rapidly, and the chest wall mass decreased in size. Her CT scan confirmed her improvement (Fig. 2b) .
After five cycles of chemotherapy, a left thoracotomy was performed. A residual mass arising from the ninth rib was found, contiguous with lung, pericardium, diaphragm and spleen. Her seventh to tenth ribs were removed, along with the associated muscles, left phrenic nerve and central portion of the diaphragm. A chest wall prosthesis of Marlex and methyl methacrylate was inserted. She made a rapid recovery, and had her sixth cycle of chemotherapy 12 days after the operation. Examination of the resection specimen revealed that the excision margin was narrowest at the deep surface, with viable tumour still present.
In view of the marginal excision, hyperfractionated radiotherapy to her chest wall was given concurrently with cycles 8 to 10 of chemotherapy. She received a total of 49.6 Gy in 31 twice daily fractions in 3 blocks, with a lO-day gap scheduled after the first and second blocks. The first 45 Gy were given in two 14-day blocks to large (19 cm x 18 cm) antero-posterior fields. The second block was delayed by one week because of pain 
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... Fig. 4 . EVAIA chemotherapy -Arm C of a multinational prospective randomised study of Ewing's sarcoma, EICESS 92. Etop = etoposide, 150 mglm2/day days 1,2,3: VCR = vincristine, 1.5 mg/ m 2 (maximum 2 mg) day 1; Dox = doxorubicin, 20 mg/m2/day days 1, 2, 3 during odd cycles: Actin = actinomycin D, 0.5 mglm2/day days 1,2,3 during even cycles; Hos = ifosfamide 2 glm2/day days 1, 2, 3. Mesna uroprotection is given with ifosfamide.
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around the prosthesis. Ultrasound of her chest revealed fluid which was inaccessible to a needle because of the prosthesis, and she improved with no specific therapy. Her final block of radiotherapy (4.6 Gy) was given to a smaller field of 14 cm x 7 cm, as planned. She had severe toxicity during her treatment. WHO grade 3-4 mucositis was a recurring problem, she had two episodes of febrile neutropenia, and required blood transfusion after every cycle of chemotherapy, despite dose reductions. The worst toxicity accompanied cycles given with radiotherapy. She required a platelet transfusion after her eleventh cycle, and etoposide was omitted for the rest of her treatment. By the end of her treatment, she was receiving 60% of her initial doses of ifosfamide, actinomycin D and doxorubicin. She remained amenorrhoeic for five months after completion of chemotherapy. Since completion of chemotherapy, she has also developed cough and haemoptysis, with consolidation around the prosthesis, and is practising postural drainage.
She completed chemotherapy in May 1994, at which stage a CT scan of her chest showed some increased soft tissue shadowing along the internal surface of her prosthesis, with no evidence of tumour. In October 1995, a single 3-cm right-sided pulmonary metastasis was identified. Isotope bone scanning revealed a further metastasis in the left parietal bone. There was no evidence of recurrence at the site of the original tumour. Further chemotherapy has been initiated and consolidation with high-dose melphalan and etoposide is planned, should a further remission be achieved.
Discussion
The concept of primitive neuroectodermal tumour (PNET) has been evolving for many years, as has its nomenclature. It was first described as a tumour arising in peripheral nerve, when it was called neuroepithelioma [1] . These tumours are part of the differential diagnosis of malignant small round cell tumours, which include Ewing's sarcoma, rhabdomyosarcoma, neuroblastoma and lymphoma, and which appear as sheets of
